1. daily corticosteroids at a dose equivalent to prednisone 20 mg/day or greater during the period two weeks before enrollment to the trial. intermittent steroid dosing at or above this level is permitted (i.e., weekly dexamethasone dosing as part of myeloma therapy) 2. history of previous severe reaction to any available covid-19 vaccine (defined as any grade 3 or higher reaction) 3. febrile illness within 3 days of booster dosing. 4. documented sars-cov2 infection within 2 weeks of enrollment. 5. less than 3 months post-autologous or allogeneic stem cell transplant (note: transplant between initial standard vaccine administration and enrollment is not otherwise grounds for exclusion from participation).

1. daily corticosteroids at a dose equivalent to prednisone 20 mg/day or greater during the period two weeks before enrollment to the trial. intermittent steroid dosing at or above this level is permitted (i.e., weekly dexamethasone dosing as part of myeloma therapy) 2. history of previous severe reaction to any available covid-19 vaccine (defined as any grade 3 or higher reaction) 3. febrile illness within 3 days of booster dosing. 4. documented sars-cov2 infection within 2 weeks of enrollment. 5. less than 3 months post-autologous or allogeneic stem cell transplant (note: transplant between initial standard vaccine administration and enrollment is not otherwise grounds for exclusion from participation).

daily corticosteroids at a dose equivalent to prednisone 20 mg/day or greater during the period two weeks before enrollment to the trial. intermittent steroid dosing at or above this level is permitted (i.e., weekly dexamethasone dosing as part of myeloma therapy) history of previous severe reaction to any available covid-19 vaccine (defined as any grade 3 or higher reaction) febrile illness within 3 days of booster dosing. documented sars-cov2 infection within 2 weeks of enrollment. less than 3 months post-autologous or allogeneic stem cell transplant (note: transplant between initial standard vaccine administration and enrollment is not otherwise grounds for exclusion from participation).

daily corticosteroids at a dose equivalent to prednisone 20 mg/day or greater during the period two weeks before enrollment to the trial. intermittent steroid dosing at or above this level is permitted (i.e., weekly dexamethasone dosing as part of myeloma therapy) history of previous severe reaction to any available covid-19 vaccine (defined as any grade 3 or higher reaction) febrile illness within 3 days of booster dosing. documented sars-cov2 infection within 2 weeks of enrollment. less than 3 months post-autologous or allogeneic stem cell transplant (note: transplant between initial standard vaccine administration and enrollment is not otherwise grounds for exclusion from participation).

1. daily corticosteroids at a dose equivalent to prednisone 20 mg/day or greater during the period two weeks before enrollment to the trial. intermittent steroid dosing at or above this level is permitted (i.e., weekly dexamethasone dosing as part of myeloma therapy) 2. history of previous severe reaction to any available covid-19 vaccine (defined as any grade 3 or higher reaction) 3. febrile illness within 3 days of booster dosing. 4. documented sars-cov2 infection within 2 weeks of enrollment. 5. less than 3 months post-autologous or allogeneic stem cell transplant (note: transplant between initial standard vaccine administration and enrollment is not otherwise grounds for exclusion from participation).

1. daily corticosteroids at a dose equivalent to prednisone 20 mg/day or greater during the period two weeks before enrollment to the trial. intermittent steroid dosing at or above this level is permitted (i.e., weekly dexamethasone dosing as part of myeloma therapy) 2. history of previous severe reaction to any available covid-19 vaccine (defined as any grade 3 or higher reaction) 3. febrile illness within 3 days of booster dosing. 4. documented sars-cov2 infection within 2 weeks of enrollment. 5. less than 3 months post-autologous or allogeneic stem cell transplant (note: transplant between initial standard vaccine administration and enrollment is not otherwise grounds for exclusion from participation).